Welcome to VanEck
Select Investor Type
Invests in companies advancing genomics, biotechnology and broader healthcare innovation. Biotech and innovation stocks can be highly volatile and binary on trial outcomes.
Breakthroughs in gene editing and diagnostics open large long-term growth opportunities in healthcare. Many holdings are pre-profit and carry significant clinical and regulatory risk.
Focuses on genuine innovators rather than diversified pharma, for a targeted growth play. Concentration in a high-risk sector can amplify drawdowns.
Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.The Fund has a sustainable investment objective, with an emphasis on social objectives:
Main Risk Factors: Equity market risk, industry concentration risk, Liquidity Risks. Investors must consider all the fund's characteristics or objectives as detailed in the prospectus or related documents before making an investment decision. Please refer to the sustainability-related disclosures in the document section, to the
and the Prospectus for other important information before investing.